Development of approaches for studying the biodistribution of a bicistronic therapeutic plasmid construct in the mouse body

Relevance. The use of gene therapy drugs for the treatment of genetic diseases and stimulation of regeneration processes is lengthy and involves repeated injections, which may lead to increased dissemination of gene therapy constructs from the injection site and undesirable ectopic expression of growth factors encoded in them. Existing approaches to study the pharmacokinetics of a drug to assess the dissemination of a gene therapy drug from the site of administration are not applicable. Objective: to evaluate the suitability of the real-time PCR method for studying the biodistribution of a promising gene therapy drug in mice during a course of use. Methods. Male F1 CBA×C57/Black mice after nerve injury were injected with the test plasmid into the denervated tibial muscle after nerve injury, as well as after 4, 9 and 13 days at a dosage of 60 and 120 μg/mouse. After 7, 14, and 28 days, organ and tissue samples were removed, total DNA was isolated, and plasmid DNA content was assessed by real-time PCR. Results. We have shown that the studied genetic construct is able to disseminate from the injection site. We have found that the peak of dissemination for this construct in the organs and tissues of the mouse is reached 14–28 days after the end of the course application, while ectopic expression of growth factors is not observed in them. Conclusion. The proposed method is specific, highly sensitive, and linear over a wide range of concentrations. Thus, it can be recommended for studying the biodistribution of potential gene therapy drugs in the body of experimental animals as part of a preclinical studies complex.

1. Odinak MM, Zhivolupov SA. Zabolevaniya i travmy perifericheskoj nervnoj sistemy. Saint-Petersburg: Izdatel'stvo «SpecLit»; 2009. (In Russ).

2. Shevelev IN. Travmaticheskie porazheniya plechevogo spleteniya. Moscow: Izdatel'stvo «Moskva»; 2005. (In Russ).

3. Karagyaur M, Rostovtseva A, Semina E, Klimovich P et al. A bicistronic plasmid encoding brain-derived neurotrophic factor and urokinase plasminogen activatorstimulates peripheral nerve regeneration after injury. J Pharmacol Exp Ther. 2020;372(3):248–255. DOI: 10.1124/jpet.119.261594.

4. Boyd JG, Gordon T. Neurotrophic factors and their receptors in axonal regeneration and functional recovery after peripheral nerve injury. Mol Neurobiol. 2003;27(3):277–324. DOI: 10.1385/MN:27:3:277.

5. Frostick SP, Yin Q, Kemp GJ. Schwann cells, neurotrophic factors, and peripheral nerve regeneration. Microsurgery. 1998;18(7):397–405. DOI: 10.1002/(sici)1098-2752(1998)18:7<397::aid-micr2>3.0.co;2-f.

6. Huang Q, Wei H, Wu Z, et al. Preferentially Expressed Antigen of Melanoma Prevents Lung Cancer Metastasis. PLoS One. 2016;11(7):e0149640. DOI: 10.1371/journal.pone.0149640.

7. Maripuu A, Björkman A, Björkman-Burtscher IM, Mannfolk P et al. Reconstruction of sciatic nerve after traumatic injury in humans - factors influencing outcome as related to neurobiological knowledge from animal research. J Brachial Plex Peripher Nerve Inj. 2012 Oct 10;7(1):7. DOI: 10.1186/1749-7221-7-7.

8. EMEA. Guideline on bioanalytical method validation. 2011.

9. US FDA. Guidance for industry: Q2B validation of analytical procedures: methodology. Rockville. MD: Nov 1996.

10. OECD. Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment. 2005.

11. Schechtman LM. Internationally harmonized processes for test method evaluation. Validation and regulatory acceptance: The role of OECD guidance document 34. Japanese Society for Alternatives to Animal Experiments, 14, Special Issue. Рр. 475–782 (2008).

12. Hamide Z. Senyuva, Gilbert D. Prostoe rukovodstvo dlya pol'zovatelej po razrabotke i validacii metodov / Perevod na russkij yazyk pod red. A. Galkin. Moscow: Izdatel'stvo «OOO Torius 77»; 2011. (In Russ).

13. Ermer J, Nethercote PW. Method Validation in Pharmaceutical Analysis. Wiley, 2014.